Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GKL-006Allo Injection in Patients With Ankylosing Spondylitis

NCT07915544 is registered in ClinicalTrials.gov with Beijing Gene Key Life Technology Co., Ltd as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07915544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Lead sponsor
Beijing Gene Key Life Technology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
March 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis

Arms

As registered; 1 arm.

  • GKL-006Allo Injection ExperimentalGKL-006Allo

    Participants receive GKL-006Allo injection by intravenous infusion once every two weeks for up to 11 doses. Participants are assigned to one of two dose levels, a low dose of (3.0±0.9)×10\^8 cells/m2 or a high dose of (9.0±2.7)×10\^8 cells/m2, with the low-dose level enrolled first and the high-dose level opened after safety review per the dose-escalation rules.

Primary endpoints

Registered primary outcome measures; 10 primary.

  • Dose-limiting toxicities (DLTs) of GKL-006Allo injection 28 days after the first dose of GKL-006Allo

    Number and percentage of participants experiencing DLTs at each dose level during the DLT observation window, assessed per protocol-defined criteria.

  • Frequency of adverse events (AEs) and serious adverse events (SAEs) From first dose through end of study (approximately 52 weeks after first dose)

    Number and percentage of participants with AEs and SAEs, including treatment-emergent events, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

  • Change from baseline in systolic blood pressure Baseline through end of study (approximately 52 weeks after first dose)

    Vital signs will be measured at each scheduled visit. Descriptive statistics will be provided for observed values and changes from baseline.Units: mmHg.

  • Change from baseline in diastolic blood pressure Baseline through end of study (approximately 52 weeks after first dose)

    Vital signs will be measured at each scheduled visit. Descriptive statistics will be provided for observed values and changes from baseline.Units: mmHg.

  • Change from baseline in pulse rate Baseline through end of study (approximately 52 weeks after first dose)

    Vital signs will be measured at each scheduled visit. Descriptive statistics will be provided for observed values and changes from baseline.Units: beats per minute (bpm).

+5 more primary endpoints

Lead sponsor's other trials

Beijing Gene Key Life Technology Co., Ltd, most recent start first.

Similar trials

Same condition (Spondylitis, Ankylosing) and phase, most recent start first.